Canakinumab ANti-inflammatory Thrombosis Outcomes Study(English)

• provided the first proof of the success of targeting inflammatory pathways in cardiovascular disease by administration of a neutralizing antibody for the inflammasome product IL-1β in individuals with established coronary artery disease and persistent inflammation despite standard-of-care therapy, including high-intensity statin treatment
• CAD
• Thrombocyte /thrombosis, Inflammasome
• https://doi.org…bts.2020.03.017